Tricida, Inc. (TCDA): Price and Financial Metrics
GET POWR RATINGS... FREE!
TCDA Stock Price Chart Interactive Chart >
TCDA Price/Volume Stats
| Current price | $4.43 | 52-week high | $9.81 |
| Prev. close | $4.47 | 52-week low | $3.55 |
| Day low | $4.40 | Volume | 110,800 |
| Day high | $4.65 | Avg. volume | 454,446 |
| 50-day MA | $4.13 | Dividend yield | N/A |
| 200-day MA | $5.24 | Market Cap | 223.40M |
Tricida, Inc. (TCDA) Company Bio
Tricida, Inc., a late-stage pharmaceutical company, focuses on developing therapeutics to address renal, metabolic, and cardiovascular disease. Its lead product candidate, TRC101, a non-absorbed orally-administered polymer drug that is in Phase III clinical trials used to treat metabolic acidosis in patients with chronic kidney disease. The company was founded in 2013 and is based in South San Francisco, California.
Latest TCDA News From Around the Web
Below are the latest news stories about Tricida Inc that investors may wish to consider to help them evaluate TCDA as an investment opportunity.
Tricida to Present at the H.C. Wainwright 23rd Annual Global Investment ConferenceSOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company’s key initiatives. The presentation will be accessible on the Tricida website at IR.Tricida.com on Monday, September 13, 2021 at 4:00 am PT / 7:00 am ET. An archive of the presentation will be available for 90 days follo |
Estimating The Fair Value Of Tricida, Inc. (NASDAQ:TCDA)How far off is Tricida, Inc. ( NASDAQ:TCDA ) from its intrinsic value? Using the most recent financial data, we'll take... |
Tricida Announces Second Quarter 2021 Financial ResultsWebcast Today at 4:30 pm Eastern TimeSOUTH SAN FRANCISCO, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today financial results for the three and six months ended June 30, 2021 and provided an |
Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 9, 2021SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2021 financial results after the close of market on Monday, August 9, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows: Tricida Conference Call Information Tricida will host its Second Quarter Financial Res |
Do Hedge Funds Love Tricida, Inc. (TCDA)?Although the masses and most of the financial media blame hedge funds for their exorbitant fee structure and disappointing performance, these investors have proved to have great stock picking abilities over the years (that’s why their assets under management continue to swell). We believe hedge fund sentiment should serve as a crucial tool of an […] |
TCDA Price Returns
| 1-mo | 10.20% |
| 3-mo | -7.32% |
| 6-mo | -15.62% |
| 1-year | -51.16% |
| 3-year | -86.44% |
| 5-year | N/A |
| YTD | -37.16% |
| 2020 | -81.32% |
| 2019 | 60.05% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...